In the high TLR4 expression subgroup, five-year DSS reached 88.9% (95% CI 77.1–100.0) among patients with the highest CD3–CD8 tumor–stroma index, falling to 39.7% (95% CI 26.4–53.0; p < 0.001, log-rank test; Fig 3d) among patients with the lowest CD3–CD8 tumor–stroma index. The gene discussed is CD8A; the disease is neoplasm.